In Korea, genomic medicine is a fast-growing and popular field: genomic research, genetic testing and precision medicine, and direct-to-consumer genetic testing, are significant areas of policy attention, while in terms of genomic research, Korea has one of the biggest biobanks in the world. Genetic testing is widespread and increasing, both for hereditary (mostly infant) diseases, and following cancer diagnoses to personalise treatment. A regulatory framework has been developed for these tests, but quality assurance of private testing laboratories and training for health professionals are less well-developed and, most importantly, health coverage does not appear to be keeping pace with demand from patients and clinicians, and the cost-effectiveness of widespread use of genetic testing to personalise treatment (in particular cancer) does not appear to have been established. The area which generates the most concern when it comes to genomic medicine in Korea is the booming field of direct‑to‑consumer tests genetic tests.